Korea's AriBio Progresses Phase III Program For Oral Alzheimer's Contender
Executive Summary
South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.